Why the study?
Heart failure affects over 64 million people globally with rising prevalence and geographical variations, yet substantial epidemiological data remain lacking from developing countries.
Heart failure remains a major global public health priority affecting over 64 million people, with increasing prevalence despite stabilizing incidence in industrialized nations.
Alerts systems to rising HF burden for planning; leaves open targeted prevention research in aging populations.
Heart Failure (HF) is a multi-faceted and life-threatening syndrome characterized by significant morbidity and mortality, poor functional capacity and quality of life, and high costs. HF affects more than 64 million people worldwide. Therefore, attempts to decrease its social and economic burden have become a major global public health priority. While the incidence of HF has stabilized and seems to be declining in industrialized countries, the prevalence is increasing due to the ageing of the population, improved treatment of and survival with ischaemic heart disease, and the availability of effective evidence-based therapies prolonging life in patients with HF. There are geographical variations in HF epidemiology. There is substantial lack of data from developing countries, where HF exhibits different features compared with that observed in the Western world. In this review, we provide a contemporary overview on the global burden of HF, providing updated estimates on prevalence, incidence, outcomes, and costs worldwide.
No takes yet. Share an insight, caveat, or question.
Savarese et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: